Hartford US Value ETF(VMAX.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Hartford US Value ETF
VMAX.US
News
View More

Earnings Flash (STT) State Street Posts Q4 Total Revenue $3.67B, vs. FactSet Est of $3.60B

Earnings Flash (STT) State Street Posts Q4 Total Revenue $3.67B, vs. FactSet Est of $3.60B

marketscreener·
US
STT
-6.07%
marketscreener·
US
STT
-6.07%

UnitedHealthcare to Support Rural Hospitals with Accelerated Medicare Advantage Payments, Providing Immediate Cash-Flow Relief

UnitedHealthcare has launched the Rural Payment Acceleration Pilot to support independent rural hospitals by accelerating Medicare Advantage payment timelines from less than 30 days to under 15 days. This initiative aims to provide immediate cash-flow relief and enhance the sustainability of these hospitals. CEO Bobby Hunter emphasized the importance of rural hospitals in communities and the goal of improving patient care. The pilot will inform future expansions to additional hospitals, reinforcing UnitedHealthcare's commitment to rural health stability.

Press Releases·
US
UNH
-2.34%
Press Releases·
US
UNH
-2.34%

A Google-backed space stock is up 600% in a year. Here's why it could go even higher.

Planet Labs' stock has surged 588% over the past year, driven by optimism over its government contracts and new satellite technology. Wedbush analyst Dan Ives raised the price target to $28, citing strong demand for its services. The company recently secured a multiyear deal with Sweden's military worth over $500 million, adding to its existing contracts with the U.S. Planet Labs aims to launch advanced satellites capable of delivering AI-analyzed images within an hour. Google, a major investor, is collaborating on Project Suncatcher to develop solar-powered satellite constellations.

Dow Jones·
US
GOOG
-0.85%
US
GOOGL
-0.84%
US
PL
+1.77%
Dow Jones·
US
GOOG
-0.85%
US
GOOGL
-0.84%
US
PL
+1.77%

JPM26: HIV pipeline dosing optionality gives Gilead advantage

At the J.P. Morgan Healthcare Conference 2026, Gilead's CEO Daniel O’Day highlighted the company's competitive advantage in HIV treatment with seven pipeline drugs. Gilead's offerings include various dosing options for both treatment and prevention, such as the recently launched Yeztugo, which achieved $150 million in sales in 2025. The company anticipates significant growth in the HIV market, with a forecasted increase from $26.5 billion in 2023 to $32.1 billion by 2033, driven by innovative therapies and expanding access in regions like sub-Saharan Africa.

Pharmaceutical Technology·
US
GILD
+3.01%
Pharmaceutical Technology·
US
GILD
+3.01%

BMS reports positive results in Phase III SCOUT-HCM trial for oHCM

Bristol Myers Squibb (BMS) has reported positive results from the Phase III SCOUT-HCM trial for Camzyos (mavacamten) in treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescents aged 12 to under 18. The trial met its primary endpoint, showing significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at week 28 compared to placebo. Safety data remained consistent with adult profiles, and BMS plans to present comprehensive results at a medical congress. The study continues with active treatment and long-term extension phases.

WorldPharmaceuticals·
US
BMY
-2.40%
WorldPharmaceuticals·
US
BMY
-2.40%
© 2026 Longbridge｜Disclaimer